Are certain drugs associated with enhanced mortality in COVID-19?

QJM. 2020 Jul 1;113(7):509-510. doi: 10.1093/qjmed/hcaa103.

Authors

M R Goldstein¹, G A Poland², C W Graeber³

Affiliations

¹ NCH Physician Group, Center for Healthy Living, 132 Moorings Park Drive, Naples, FL 34105, USA.
² Mayo Vaccine Research Group, Mayo Clinic and Foundation, 611C Guggenheim Building, Rochester, MN 55905, USA.
³ Mayo Clinic College of Medicine and Science, University of Central Florida, College of Medicine, NCH Healthcare System Internal Medicine Residency, Affiliate of the Mayo Clinic School of Medicine and Science, Naples, FL 34102, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Interleukin-18
Pandemics*
Pneumonia, Viral*
Respiratory Distress Syndrome*
SARS-CoV-2

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Interleukin-18